ClinicalTrials.gg
RecruitingNCT06962488PRISM-BPUpdated Oct 9, 2026

Polygenic Risk Score Implementation and Stratification for Managing Blood Pressure

An interventional study of Regular Care and SBP PRS Dissemination in Hypertension and Atherosclerotic Cardiovascular Disease, sponsored by University of Alabama at Birmingham. Recruiting at 1 site in United States. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by University of Alabama at Birmingham · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 44 studies in Hypertension by University of Alabama at Birmingham — 13 open to participants now, 16 under way, 1 of them phase 3. Hypertension · University of Alabama at Birmingham.

Planned enrollment
7th of 38
300 · median 71
Started
2025
with 1 other
No phase
29 of 44
11 open now
Primary completion
2030-03
later than 12 of 15 live
Registered
35th of 44
by date

Among the 44 studies in Hypertension by University of Alabama at Birmingham, this one is the 7th largest by planned enrollment of the 38 interventional ones that give a count, is one of 2 that started in 2025, is one of 29 with no phase, reaches primary completion later than 12 of the 15 other live ones, and was the 35th registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.

Browse Hypertension studies →

Open to participants now

13 of the 44 studies in Hypertension by University of Alabama at Birmingham are open now, in 1 country. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 13 open studies →

Where they have run

Who these studies take

Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Hypertension by University of Alabama at Birmingham, or all of them as a file.
02

Study summary

In a multi-ethnic population, a genome-wide polygenic risk score (PRS) for systolic blood pressure (SBP), incorporating over one million common genetic variants, predicts blood pressure (BP) traits and the risk of adverse cardiovascular events beyond traditional risk factors. Delivering SBP PRS information to young and middle-aged adults with hypertension (HTN) and poor cardiovascular health (CVH) may enhance their motivation to adopt healthier lifestyles, improve blood pressure control, and ultimately reduce the risk of future cardiovascular disease (CVD). This randomized controlled trial will assess the impact of SBP PRS disclosure and theory-based genomic counseling on systolic blood pressure and health behaviors. A total of 300 adults aged 18-55 years will be enrolled and randomized to receive either routine clinical care or SBP PRS results with structured genomic counseling based on the Health Belief Model (HBM). Participants will be followed for 12 months. The primary outcome is change in 24-hour mean SBP from baseline to one year. Secondary outcomes include changes in physical activity, diet, medication adherence, smoking, lipid and glucose levels, and body composition. The study will also evaluate how behavior change is influenced by health beliefs, including perceived risk and self-efficacy. This study aims to advance the use of genomic tools in hypertension management and cardiovascular disease prevention.

Read the detailed description

This parallel-arm, randomized clinical trial is designed to assess the change in SBP following BP PRS dissemination and genomic counseling. Investigators will enroll 300 young and middle-aged adults (age: 18-55 years; 50% females; 50% non-White) with HTN [stratified by race, sex, and SBP PRS group (high vs. low/intermediate)] and poor CVH [American Heart Association's (AHA) Life Essential 8 Score: 0-50]. Participants will be randomized to A) routine clinical care (N=150), or B) SBP PRS dissemination (regular care + SBP PRS delivery and genetic counseling; N=150). After obtaining informed consent, the eligible participants will undergo genotyping and computation of their genome-wide SBP PRS. The SBP PRS results will be available within 10-15 days of screening. Participants will then be randomized in a 1:1 manner [stratified by sex, racial/ethnic group (White vs. non-White), and SBP PRS (high vs. low/intermediate)] to either the SBP PRS dissemination arm or the routine care arm. Participants will undergo a comprehensive baseline health assessment, including measurement of key HBM constructs, using the recently developed Attitudes and Beliefs about the CVD (ABCD) Risk Questionnaire, a 26-item instrument validated in the clinical setting with four subscales: perceived risk of heart attack/stroke, perceived benefits and intentions to exercise, healthy eating intentions, and perceived benefits and intentions to reducing smoking. Investigators will also assess the perceived severity of CVD, perceived barriers to prevention behaviors, and self-efficacy to perform preventive behaviors using subscales previously assessed for content and face validity by an expert review panel and patient focus groups. Physical activity status and sleep duration (using 7-day Actigraphy), detailed dietary history [using the United States Department of Agriculture (USDA) Healthy Eating Index and collected through the validated Nutrition Coordinating Center Nutrition Data System for Research (NCC NDSR) dietary assessment tool], health-related quality of life [using 36-Item Short Form Survey (SF-36), and the Centers for Disease Control and Prevention (CDC) Health-Related Quality of Life-14 (HRQOL-14)], medication adherence using the Medication Adherence Rating Scale (MARS), 24-hour ambulatory blood pressure monitoring (ABPM), current health behaviors (smoking, alcohol, recreational drugs), and other cardiometabolic health parameters [lipid profile, hemoglobin A1c (HbA1c), body mass index (BMI), and body composition), and anxiety [using the Beck Anxiety Inventory (BAI)].

03

Conditions studied

  • Hypertension
  • Atherosclerotic Cardiovascular Disease

Keywords

  • Systolic Blood Pressure
  • Polygenic Risk Score
  • Genomic Counseling
  • Health Belief Model
  • Cardiovascular Health
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 to 55 years (inclusive) at the time of screening.
  • Diagnosis of hypertension defined by 2017 ACC/AHA guidelines, as evidenced by Resting office systolic blood pressure (SBP) of 130-160 mm Hg or Resting office diastolic blood pressure (DBP) of 80-100 mm Hg or Current use of antihypertensive medication.
  • Poor cardiovascular health, defined as Life's Essential 8 score \<50.
  • Willing and able to undergo 24-hour ambulatory blood pressure monitoring (ABPM) to confirm hypertension.
  • Able to provide .

Exclusion criteria

Exclusion Criteria:

  • History of cardiovascular disease, including Myocardial infarction, Angina, Cardiac arrhythmia, Coronary heart disease, Heart failure, Stroke, or .
  • (BMI) \<18.5 kg/m² or >45 kg/m².
  • Baseline office SBP >160 mm Hg or DBP >100 mm Hg.
  • Use of more than two antihypertensive medication classes.
  • Not hypertensive based on 24-hour ABPM (per 2017 ACC/AHA criteria).
  • Pregnant or breastfeeding.
  • Estimated (eGFR) \<60 mL/min/1.73 m² (using CKD-EPI equation).
  • Urine albumin-to-creatinine ratio ≥30 mg/g.
  • Hepatic transaminase levels >3× the .
  • Significant psychiatric illness (assessed via Global Health Questionnaire-12).
  • Moderate or severe anxiety (Beck Anxiety Inventory [BAI] score >16).
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    SBP PRS Dissemination

    Participants randomized to this arm will receive their personalized SBP polygenic risk score (PRS), along with structured genomic counseling sessions guided by the Health Belief Model and routine clinical care. Counseling will be delivered by trained genetic counselors at baseline and during 3-monthly in-person follow-up visits. The counseling is designed to increase perceived susceptibility, reduce perceived barriers, and improve self-efficacy for health behavior change.

    Behavioral: SBP PRS Dissemination

  • Active comparator
    Routine Clinical Care

    Participants randomized to this arm will receive standard clinical care for hypertension, including educational materials on blood pressure control, lifestyle modification, and cardiovascular health. These materials will be adapted from the American Heart Association Life's Essential 8 and the ACC preventive cardiology toolkit. Participants will not receive SBP PRS results or genomic counseling during the study. At the end-of-study visit (12 months), participants in this group will be offered their SBP PRS results and optional genomic counseling.

    Behavioral: Regular Care

Interventions

  • BehavioralRegular Care

    Educational brochures and lifestyle guidance on blood pressure control, medication adherence, physical activity, and healthy diet, provided at baseline only. No additional counseling or genetic risk disclosure will occur during the 12-month intervention period.

  • BehavioralSBP PRS Dissemination

    Participants receive individualized SBP PRS reports and structured genomic counseling sessions delivered by trained genetic counselors. Counseling addresses key constructs of the Health Belief Model, including perceived susceptibility, severity, and benefits of behavior change, with an emphasis on lifestyle modification and medication adherence.

06

What researchers measure

Primary outcomes

  1. Change in Mean 24-Hour Systolic Blood Pressure

    The difference in the 24-hour mean systolic BP between the two study groups at 1 year, adjusted for baseline.

    Time frame: 1 year

Secondary outcomes

  1. Change in Physical Activity Levels

    Physical activity levels in MET·hr-1·wk-1 estimated using 7-day actigraphy. The difference in the physical activity levels (MET·hr-1·wk-1) between the two study groups at 1 year, adjusted for baseline.

    Time frame: 1 year

  2. Change in Healthy Diet Index Score

    The USDA Healthy Eating Index (HEI-2015) will be used to estimate changes in diet quality. The HEI score ranges from 0 to 100, with higher scores indicating better adherence to the Dietary Guidelines for Americans (i.e., better diet quality). The outcome measure will be the difference in HEI scores between the two study groups at 1 year, adjusted for baseline

    Time frame: 1 year

  3. Change in Medication Adherence

    Medication adherence will be assessed using the Medication Adherence Report Scale (MARS-5). The MARS-5 scale has a score range from 5 to 25, with higher scores indicating better adherence. The outcome measure will be the difference in MARS-5 scores between the two study groups at 1 year, adjusted for baseline

    Time frame: 1 year

  4. Change in Ambulatory Blood Pressure Parameters

    The difference in the 24-hour mean diastolic BP, daytime systolic BP, daytime diastolic BP, nighttime systolic BP, and nighttime diastolic BP between the two study groups at 1 year, adjusted for baseline.

    Time frame: 1 year

  5. Change in Lipid Profile

    The difference in the low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglyceride, and total cholesterol levels between the two study groups at 1 year, adjusted for baseline.

    Time frame: 1 year

  6. Change in Sleep Duration

    The difference in the sleep duration estimated using 7-day actigraphy, between the two study groups at 1 year, adjusted for baseline.

    Time frame: 1 year

  7. Change in Body Mass Index

    The difference in the body mass index between the two study groups at 1 year, adjusted for baseline.

    Time frame: 1 year

  8. Change in Fat Mass

    The difference in the fat mass between the two study groups at 1 year, adjusted for baseline.

    Time frame: 1 year

  9. Change in Lean Mass

    The difference in the lean mass between the two study groups at 1 year, adjusted for baseline.

    Time frame: 1 year

  10. Change in Health Belief Model Constructs

    The difference in the Health Belief Model constructs, measured using standardized questionnaires, between the two study groups at 1 year, adjusted for baseline.

    Time frame: 1 year

  11. Change in Smoking Behavior

    Estimated as the number of cigarettes per week. The difference in the number of cigarettes per week between the two study groups at 1 year, adjusted for baseline.

    Time frame: 1 year

  12. Change in Health-Related Quality of Life (SF-36)

    Assessed using the 36-Item Short Form Survey (SF-36). The SF-36 produces scores ranging from 0 to 100, with higher scores indicating better quality of life. The difference between study groups at 1 year will be assessed, adjusted for baseline.

    Time frame: 1 year

  13. Change in Health-Related Quality of Life (CDC HRQOL-14)

    Assessed using the Centers for Disease Control and Prevention Health-Related Quality of Life 14-item measure (CDC HRQOL-14). The number of physically and mentally unhealthy days is recorded, with higher numbers indicating worse quality of life. The difference between study groups at 1 year will be assessed, adjusted for baseline.

    Time frame: 1 year

  14. Change in Anxiety

    Anxiety will be assessed using the Beck Anxiety Inventory (BAI). The BAI scores range from 0 to 63, with higher scores indicating greater severity of anxiety symptoms. The outcome measure will be the difference in BAI scores between the two study groups at 1 year, adjusted for baseline.

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Shetty NS, Pampana A, Patel N, Yerabolu K, Patel G, Irvin MR, Natarajan P, Lin HJ, Guo X, Rich SS, Rotter JI, Li P, Arora G, Arora P. Sex Differences in the Association of Multiethnic Genome-Wide Blood Pressure Polygenic Risk Score With Population-Level Systolic Blood Pressure Trajectories. Circ Genom Precis Med. 2024 Apr;17(2):e004515. doi: 10.1161/CIRCGEN.123.004515. Epub 2024 Feb 19. No abstract available. PubMed 38372177 ↗
  • Shetty NS, Pampana A, Patel N, Li P, Yerabolu K, Gaonkar M, Arora G, Arora P. Sex Differences in the Association of Genome-Wide Systolic Blood Pressure Polygenic Risk Score With Hypertension. Circ Genom Precis Med. 2023 Dec;16(6):e004259. doi: 10.1161/CIRCGEN.123.004259. Epub 2023 Oct 9. No abstract available. PubMed 37807951 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Mar 2030, 55 months after the start.

Of 1,407 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 55 months is above that.

Counting every sponsor, half of 1,502 studies reached it within 23 months; a quarter within 10 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 21, 2025
First posted
May 8, 2025
StartActual
Aug 1, 2025
Primary completionEst.
Mar 31, 2030
CompletionEst.
Jul 31, 2030
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06962488
Responsible party
Pankaj Arora, MD (Associate Professor, Division of Cardiovasular Disease, Department of Medicine, University of Alabama at Birmingham) — Principal investigator
First posted
May 8, 2025
Start date
Aug 1, 2025
Primary completion
Mar 31, 2030 (estimated)
Completion
Jul 31, 2030 (estimated)
Last update
Oct 9, 2026

Study contacts

Nehal Vekariya, MS
Contact
nvekariya@uabmc.edu
2059347173
Pankaj Arora, MD, FAHA
principal investigator · University of Alabama at Birmingham

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion